Trial Profile
A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cytarabine; Idarubicin
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2013 New trial record